Protagonist Therapeutics, Inc vs Eli Lilly & Co.
PTGX vs LLY — side-by-side comparison from reported financials. PTGX leads 2, LLY leads 8 of 10 comparable metrics.
Protagonist Therapeutics, Inc
PTGX · Healthcare
$143.00+2.21%Strong
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | PTGX | LLY |
|---|---|---|
| Price | $143.00 | $1 177.20 |
| Market cap | $9.25B | $1.05T |
| Revenue (TTM) | $275M | $79.7B |
| Revenue growth | +20.1% | +31.7% |
| Net margin | 30.2% | 33.5% |
| Free cash flow | $131M | $18.2B |
| Net cash (debt) | — | ($35.2B) |
| 1-year price return | +113.3% | +37.6% |
| P/E | 112.2 | 41.6 |
| P/E vs own history (cheap-side %) | 21% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | 12% | 93% |
| Altman Z-score | 139.54 | 7.10 |
| CV checks passed | 6 of 10 | 11 of 10 |
| Employees | 141 | 50,000 |
Full résumé-style profiles: PTGX CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.